These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 33642364)
21. Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery. Zeng S; Zhang H; Shen Z; Huang W Front Chem; 2021; 9():639176. PubMed ID: 33777902 [TBL] [Abstract][Full Text] [Related]
22. Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer's Disease. Bhatia S; Singh M; Singh T; Singh V Neurochem Res; 2023 Jan; 48(1):13-25. PubMed ID: 35987974 [TBL] [Abstract][Full Text] [Related]
23. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779 [TBL] [Abstract][Full Text] [Related]
24. Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy. Gong B; Zhang W; Cong W; Gu Y; Ji W; Yin T; Zhou H; Hu H; Zhuang J; Luo Y; Liu Y; Gao J; Yin Y Adv Healthc Mater; 2024 Jul; ():e2400149. PubMed ID: 39007278 [TBL] [Abstract][Full Text] [Related]
25. Targeted protein degradation by PROTACs. Neklesa TK; Winkler JD; Crews CM Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226 [TBL] [Abstract][Full Text] [Related]
26. Targeted Degradation of Proteins by PROTACs. Jang ER; Lee W; Kim KB Curr Protoc Chem Biol; 2010 Jun; 2(2):71-87. PubMed ID: 23836551 [TBL] [Abstract][Full Text] [Related]
27. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960 [TBL] [Abstract][Full Text] [Related]
28. [Intermolecular interaction-based ubiquitin-proteasome system-targeting drug discovery]. Naito M; Komatsu H Nihon Yakurigaku Zasshi; 2021; 156(1):9-12. PubMed ID: 33390482 [TBL] [Abstract][Full Text] [Related]
29. Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation. Sun D; Zhang J; Dong G; He S; Sheng C J Med Chem; 2022 Nov; 65(21):14276-14288. PubMed ID: 36306471 [TBL] [Abstract][Full Text] [Related]
30. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future. Pettersson M; Crews CM Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855 [TBL] [Abstract][Full Text] [Related]
31. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337 [TBL] [Abstract][Full Text] [Related]
32. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151 [TBL] [Abstract][Full Text] [Related]
33. Protein degradation through covalent inhibitor-based PROTACs. Xue G; Chen J; Liu L; Zhou D; Zuo Y; Fu T; Pan Z Chem Commun (Camb); 2020 Feb; 56(10):1521-1524. PubMed ID: 31922153 [TBL] [Abstract][Full Text] [Related]
34. Monitoring and deciphering protein degradation pathways inside cells. Daniels DL; Riching KM; Urh M Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861 [TBL] [Abstract][Full Text] [Related]
35. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). Schiedel M; Herp D; Hammelmann S; Swyter S; Lehotzky A; Robaa D; Oláh J; Ovádi J; Sippl W; Jung M J Med Chem; 2018 Jan; 61(2):482-491. PubMed ID: 28379698 [TBL] [Abstract][Full Text] [Related]
36. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946 [TBL] [Abstract][Full Text] [Related]
37. Targeted protein degradation: mechanisms, strategies and application. Zhao L; Zhao J; Zhong K; Tong A; Jia D Signal Transduct Target Ther; 2022 Apr; 7(1):113. PubMed ID: 35379777 [TBL] [Abstract][Full Text] [Related]
38. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. An S; Fu L EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312 [TBL] [Abstract][Full Text] [Related]
39. PROTAC-DB: an online database of PROTACs. Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159 [TBL] [Abstract][Full Text] [Related]
40. Targeted protein degradation: elements of PROTAC design. Paiva SL; Crews CM Curr Opin Chem Biol; 2019 Jun; 50():111-119. PubMed ID: 31004963 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]